Cannon, C. P., Kreuzer, J., & Brückmann, M. (2016). Design and rationale of the RE-DUAL PCI trial: A prospective, randomized, phase 3b study comparing the safety and efficacy of dual antithrombotic therapy with dabigatran etexilate versus warfarin triple therapy in patients with nonvalvular atrial fibrillation who have undergone percutaneous coronary intervention with stenting. Clinical cardiology, 39(10), . https://doi.org/10.1002/clc.22572
Chicago-Zitierstil (17. Ausg.)Cannon, Christopher P., Jörg Kreuzer, und Martina Brückmann. "Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy with Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients with Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention with Stenting." Clinical Cardiology 39, no. 10 (2016). https://doi.org/10.1002/clc.22572.
MLA-Zitierstil (9. Ausg.)Cannon, Christopher P., et al. "Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy with Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients with Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention with Stenting." Clinical Cardiology, vol. 39, no. 10, 2016, https://doi.org/10.1002/clc.22572.